The U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has entered into a collaborative agreement with Glaxo Smith Kline (GSK) to evaluate the efficacy and safety of the company’s portfolio of clinical stage antibacterial assets for treating hospital and biothreat infections.
The contract is unique in Continue reading
The U.S. Navy last month awarded Stemnion, Inc. a contract for continued therapeutic development efforts in support of the Naval Medical Research Center’s cellular combat wound initiative.
The initiative seeks to obtain a novel cellular wound healing technology that will accelerate and improve healing of a variety of combat-related Continue reading
Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract with the U.S. Department of Energy, is offering an opportunity to license intellectual property for a new Fast PCR Instrument technology for commercialization. Continue reading
Last month the Obama administration released the National Bioeconomy Blueprint, a broad plan to continue fostering research and development of medical therapies and devices, biofuels and next-generation biological manufacturing processes.
The report states that the current growth of the bioeconomy is due in large part to genetic engineering, DNA sequencing, and automated high-throughput manipulations of biomolecules. Expansion of emerging Continue reading
The U.S. federal government has awarded a notable contract related to the field of chemical, biological, radiological and nuclear (CBRN) defense or life science research of interest for potential applications in biodefense: Continue reading
Novavax, Inc. this week announced it has completed purification of a virus-like particle (VLP) vaccine candidate for the emerging H7N9 influenza and has initiated animal immunogenicity and efficacy studies.
The company began work on the strain in early April. Analysis and optimization of the gene sequences for the key viral hemagglutinin (HA) and Continue reading
The Department of Defense this week announced a notable contract award related to the field of chemical, biological, radiological and nuclear (CBRN) defense or life science research of interest for potential applications in biodefense: Continue reading
Medicago Inc., a biopharmaceutical company focused on developing vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), this week announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China.
“To our knowledge, Medicago Continue reading